Trials / Completed
CompletedNCT06139315
A Study to Test How Well Different Doses of BI 765845 Are Tolerated by Healthy People
A Single-blind, Randomised, Placebo-controlled, Parallel Group Design Phase I Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Different Doses (Part A) and Different Treatment Regimens (Part B) of BI 765845 Administered to Healthy Male Subjects and Female Subjects of Non-childbearing Potential
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 765845 in healthy male subjects and female subjects of non-childbearing potential following intravenous administration of single rising doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 765845 | BI 765845 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2022-06-02
- Primary completion
- 2023-06-07
- Completion
- 2023-06-07
- First posted
- 2023-11-18
- Last updated
- 2023-11-28
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06139315. Inclusion in this directory is not an endorsement.